JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. "Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatmen ...

Entera Bio Ltd. (ENTX) closed at $1.98 in the latest trading session, marking a -1% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.02%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, added 2.03%.Shares of the company witnessed a gain of 19.76% over the previous month, beating the performance of the Medical sector with its loss of 5.2% and the S&P 500's loss of 3.15%.The investment community will be paying close attention to the earnings perform ...

Entera Bio Ltd. (ENTX) ended the recent trading session at $2.24, demonstrating a +0.9% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.22%. Meanwhile, the Dow experienced a rise of 0.06%, and the technology-dominated Nasdaq saw a decrease of 0.52%.Heading into today, shares of the company had gained 46.05% over the past month, outpacing the Medical sector's loss of 6.22% and the S&P 500's loss of 1.66% in that time.The investment community wi ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Entera Bio Ltd. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges th ...

Entera Bio (ENTX) makes oral peptide therapies, validating its disruptive N-Tab oral peptide proprietary technology platform.Its leading pipeline candidate is EB613, an oral, osteoanabolic (bone building) once-daily tablet for treating osteoporosis, a bone disease that develops when bone mass decreases, leading to an increase in the risk of fractures. A phase IIb study of the EB613 tablets met the primary and secondary endpoints.Entera Bio plans to begin a phase III registrational study on EB613 once the FD ...

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR). Miranda Toledano, CEO of Entera, commented, "We are excited to share that data ...

JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: "OPK", or "OPKO") with Entera's proprietary N-Tab™ technology. The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering fro ...

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023. "2023 was an inflection point for Entera, with consistent validation of our disruptive N-Tab™ oral peptide technology platform and the unveiling of our goal to advance five potential first-in-class oral peptide programs, Phase 1 throu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ . Commission file number 001-38556 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 00-0000000 (State or Other Jurisdiction of In ...

Exhibit 99.1 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates JERUSALEM – March 8, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023. "2023 was an inflection point for Entera, with consistent validation of our disruptive N-Tab™ oral peptide technology platform and the u ...